Program
Carboplatin
Also written as “carboplatin”, “Pemetrexed/Carboplatin” and “CARBOPLATIN”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Ovarian Neoplasms · Breast Neoplasms · Small Cell Lung Carcinoma · Neoplasms, led by 31 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 300 open or running | phase 4since Nov 24, 2009 | Apr 30, 2002 | none ahead |
| Bristol-Myers Squibb | 140 open or running | phase 4since May 28, 2014 | Sep 13, 2001 | none ahead |
| Sanofi | 70 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Sarah Cannon Research Institute | 31 open or running | phase 2since Nov 2, 2005 | Nov 2, 2005 | none ahead |
| Swedish Orphan Biovitrum | 30 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| ago-research-gmbh | 20 open or running | phase 3since Apr 16, 2013 | Apr 16, 2013 | none ahead |
| carthera | 21 open or running | phase 3since Jun 5, 2023 | Nov 13, 2018 | Jan 28, 2028phase 3 · NCT05902169 |
| Eisai | 20 open or running | phase 3since Dec 31, 2002 | Dec 31, 2002 | none ahead |
| InSightec | 20 open or running | phase 2since Jun 1, 2020 | Jun 1, 2020 | none ahead |
| Ionis Pharmaceuticals | 20 open or running | phase 3since Jun 6, 2001 | Jun 6, 2001 | none ahead |
| Johnson & Johnson | 21 open or running | phase 3since Aug 31, 2020 | Jun 12, 2008 | none ahead |
| bebetter-med-inc | 10 open or running | phase 2since Nov 11, 2024 | Nov 11, 2024 | none ahead |
| Biocad | 10 open or running | phase 3since Dec 27, 2012 | Dec 27, 2012 | none ahead |
| CASI Pharmaceuticals | 10 open or running | phase 2since Nov 13, 2002 | Nov 13, 2002 | none ahead |
| cytran | 10 open or running | phase 2since Jun 6, 2001 | Jun 6, 2001 | none ahead |
| galvanize-therapeutics-inc | 10 open or running | phase 4since Oct 13, 2022 | Oct 13, 2022 | none ahead |
| gradalis-inc | 10 open or running | phase 2since May 29, 2013 | May 29, 2013 | none ahead |
| hope-cancer-institute-inc | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Innovent Biologics | 10 open or running | phase 3since Oct 23, 2016 | Oct 23, 2016 | none ahead |
| mabscale-llc | 11 open or running | phase 3since Dec 8, 2022 | Dec 8, 2022 | Dec 2026phase 3 · NCT05654454 |
| matrix-pharmaceutical | 10 open or running | phase 2since Aug 10, 2001 | Aug 10, 2001 | none ahead |
| NovoCure | 10 open or running | phase 2since Mar 19, 2015 | Mar 19, 2015 | none ahead |
| optimum-therapeutics-llc | 10 open or running | phase 2since Dec 22, 2009 | Dec 22, 2009 | none ahead |
| Pharmacosmos | 10 open or running | phase 2since Nov 18, 2016 | Nov 18, 2016 | none ahead |
| shanghai-huaota-biopharmaceutical-co-ltd | 11 open or running | phase 3since Jan 13, 2026 | Jan 13, 2026 | Apr 10, 2028phase 3 · NCT07360132 |
| sotio-a-s | 10 open or running | phase 2since Apr 4, 2014 | Apr 4, 2014 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 3since Mar 15, 2012 | Mar 15, 2012 | none ahead |
| theradex | 10 open or running | phase 3since Oct 11, 2001 | Oct 11, 2001 | none ahead |
| UCB | 10 open or running | phase 2since Sep 6, 2005 | Sep 6, 2005 | none ahead |
| windy-hill-medical-inc | 10 open or running | phase 2since Apr 28, 2008 | Apr 28, 2008 | none ahead |
| Zydus Lifesciences | 10 open or running | phase 2since Jan 21, 2000 | Jan 21, 2000 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo, AstraZeneca, Merck, jazz-pharmaceuticals-ireland-limited, parexel, Arcus Biosciences, Ono Pharmaceutical, Pfizer, novotech-australia-pty-limited, wuxi-cds-clinical-research-shanghai-co-ltd, Valerio Therapeutics, ortho-biotech-inc, tibotec-pharmaceutical-limited and medarex.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 45 studies since Sep 12, 2005.
- Oct 23, 2016Innovent Biologics's first study: phase 3 study in NSCLCNew to Innovent BiologicsInnovent Biologics · NCT02954172 · 450 enrolled · China
- Nov 18, 2016Pharmacosmos's first study: phase 2 study in Triple Negative Breast NeoplasmsNew to PharmacosmosPharmacosmos · NCT02978716 · 102 enrolled · United States, Belgium, Bulgaria and more
- Dec 16, 2016Phase 3 study in Carcinoma, Non-Small-Cell LungBristol-Myers Squibb · NCT02998528 · 505 enrolled · United States, Argentina, Brazil and more
- Sep 26, 2018Phase 3 study in Ovarian Neoplasmsago-research-gmbh · NCT03690739 · 9 enrolled · Germany
- Nov 13, 2018carthera's first study: phase 2 study in GlioblastomaNew to cartheracarthera · NCT03744026 · 38 enrolled · United States, France
- Jun 1, 2020InSightec's first studies: 2 phase 2 studies in GlioblastomaNew to InSightecInSightec · NCT04417088, NCT04440358
- Aug 31, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT04538664 · 308 enrolled · United States, Australia, Belgium and more
- Jan 7, 2021Phase 2 study in Small Cell Lung CarcinomaBristol-Myers Squibb · NCT04702880 · 135 enrolled · United States, Australia, Belgium and more
- Nov 18, 2021Phase 2 study in Mesothelioma, MalignantBristol-Myers Squibb · NCT05136677 · 102 enrolled · China
- Oct 13, 2022galvanize-therapeutics-inc's first study: phase 4 study in Lung NeoplasmsNew to galvanize-therapeutics-incgalvanize-therapeutics-inc · NCT05583188 · 5 enrolled · United States
- Dec 8, 2022mabscale-llc's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to mabscale-llcmabscale-llc · NCT05654454 · 620 planned · Russian Federation
- Jun 5, 2023Phase 3 study in Glioblastomacarthera · NCT05902169 · 560 enrolled · United States, Austria, Belgium and more
- Nov 11, 2024bebetter-med-inc's first study: phase 2 study in Advanced Triple-Negative Breast CancerNew to bebetter-med-incbebetter-med-inc · NCT06685796 · 65 enrolled · China
- Jan 13, 2026shanghai-huaota-biopharmaceutical-co-ltd's first study: phase 3 study in Squamous Non-small Cell Lung CancerNew to shanghai-huaota-biopharmaceutical-co-ltdshanghai-huaota-biopharmaceutical-co-ltd · NCT07360132 · 480 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell Lungmabscale-llc · NCT05654454
- Jan 28, 2028Primary completion: phase 3 study in Glioblastomacarthera · NCT05902169
- Apr 10, 2028Primary completion: phase 3 study in Squamous Non-small Cell Lung Cancershanghai-huaota-biopharmaceutical-co-ltd · NCT07360132
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The newest 60 of 89 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07360132Squamous Non-small Cell Lung Cancer · China | 3 | Not yet recruiting | shanghai-huaota-biopharmaceutical-co-ltd | Apr 10, 2028 | 480 |
| NCT06685796Advanced Triple-Negative Breast Cancer · China | 2 | Completed | bebetter-med-inc | Apr 20, 2026 | 65 |
| NCT05902169Glioblastoma · United States, Austria, Belgium and more | 3 | Active, not recruiting | carthera | Jan 28, 2028 | 560 |
| NCT05654454Carcinoma, Non-Small-Cell Lung · Russian Federation | 3 | Recruiting | mabscale-llc | Dec 2026 | 620 |
| NCT05583188Lung Neoplasms · United States | 4 | Terminated | galvanize-therapeutics-inc | Feb 8, 2024 | 5 |
| NCT05136677Mesothelioma, Malignant · China | 2 | Completed | Bristol-Myers Squibb | Nov 12, 2025 | 102 |
| NCT04702880Small Cell Lung Carcinoma · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | May 22, 2025 | 135 |
| NCT04538664Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more | 3 | Active, not recruiting | Johnson & Johnson | May 3, 2023 | 308 |
| NCT04440358Glioblastoma · Canada, Italy, South Korea | 2 | Completed | InSightec | Nov 30, 2023 | 13 |
| NCT04417088Glioblastoma · United States | 2 | Completed | InSightec | Nov 30, 2023 | 28 |
| NCT03744026Glioblastoma · United States, France | 2 | Completed | carthera | Jun 23, 2021 | 38 |
| NCT03690739Ovarian Neoplasms · Germany | 3 | Terminated | ago-research-gmbh | Mar 3, 2021 | 9 |
| NCT02998528Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Sep 8, 2021 | 505 |
| NCT02978716Triple Negative Breast Neoplasms · United States, Belgium, Bulgaria and more | 2 | Terminated | Pharmacosmos | Jun 28, 2019 | 102 |
| NCT02954172NSCLC · China | 3 | Completed | Innovent Biologics | Oct 19, 2018 | 450 |
| NCT02941601Thoracic Neoplasms · United States, Belgium, Germany and more | 2 | Withdrawn | Eli Lilly | Dec 2017 | 0 |
| NCT02477826Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Oct 25, 2024 | 2,747 |
| NCT02397928Mesothelioma, Malignant · Belgium, France, Germany and more | 2 | Completed | NovoCure | Apr 2018 | 82 |
| NCT02392507Carcinoma · United States | 2 | Completed | Eli Lilly | Jan 29, 2018 | 54 |
| NCT02289456Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Bristol-Myers Squibb | Feb 22, 2017 | 40 |
| NCT02151149Carcinoma, Non-Small-Cell Lung · United States | 4 | Completed | Bristol-Myers Squibb | Jul 14, 2017 | 143 |
| NCT02107937Ovarian Neoplasms · Czechia, Poland | 2 | Completed | sotio-a-s | Nov 2020 | 136 |
| NCT01881230Breast Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Oct 28, 2016 | 191 |
| NCT01867086Ovarian Neoplasms · United States | 2 | Completed | gradalis-inc | Apr 2016 | 1 |
| NCT01837251Ovarian Neoplasms · Australia, Austria, Belgium and more | 3 | Completed | ago-research-gmbh | Jan 2021 | 682 |
| NCT01763645Carcinoma, Non-Small-Cell Lung · Belarus, India, Russian Federation and more | 3 | Completed | Biocad | Nov 2014 | 353 |
| NCT01563601Small Cell Lung Carcinoma | 3 | Withdrawn | Teva Pharmaceutical Industries | May 2016 | 0 |
| NCT01445119Glioma · United States | 1 | Completed | Eli Lilly | Jul 2013 | 58 |
| NCT01234038Carcinoma, Non-Small-Cell Lung · United States, Hungary, Poland and more | 2 | Completed | Ionis Pharmaceuticals | Oct 2012 | 116 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Jan 2014 | 280 |
| NCT01087970Head and Neck Neoplasms · United States | 2 | Completed | Eli Lilly | Aug 2013 | 69 |
| NCT01081041Head and Neck Neoplasms · United States, Canada, Mexico | 2 | Completed | Eli Lilly | Aug 2013 | 187 |
| NCT01063075Head and Neck Neoplasms · United States, Canada | 2 | Completed | Eli Lilly | May 2015 | 34 |
| NCT01075100Breast Neoplasms · United States | 2 | Completed | Sarah Cannon Research Institute | Jun 2013 | 103 |
| NCT01038752Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | optimum-therapeutics-llc | Nov 2012 | 14 |
| NCT01020786Carcinoma, Non-Small-Cell Lung · Japan | 4 | Completed | Eli Lilly | Mar 2011 | 109 |
| NCT01004380Carcinoma, Ovarian Epithelial · United States | 1 | Completed | Eisai | Aug 2012 | 15 |
| NCT00990912Pediatric Solid Tumors | 2 | Completed | Bristol-Myers Squibb | Nov 2005 | 20 |
| NCT00796991Advanced Melanoma · United States | 1 | Completed | Bristol-Myers Squibb | Nov 2009 | 72 |
| NCT00826852Lung Neoplasms · Turkey | 2 | Completed | Sanofi | Jul 2009 | 49 |
| NCT00756847Neoplasms · United States | 1 | Completed | Sanofi | May 2012 | 52 |
| NCT00698451Ovarian Neoplasms · United States | 2 | Completed | Johnson & Johnson | Oct 2010 | 54 |
| NCT00669747Carcinoma, Intraductal, Noninfiltrating · United States | 2 | UNKNOWN | windy-hill-medical-inc | Sep 2009 | 45 |
| NCT00576225NSCLC · United States | 3 | Withdrawn | Swedish Orphan Biovitrum | Apr 5, 2010 | 0 |
| NCT00494026Small Cell Lung Carcinoma · Italy, Poland, Spain and more | 2 | Terminated | Eli Lilly | Oct 2008 | 4 |
| NCT00490711Carcinoma, Ovarian Epithelial · Slovakia | 2 | Completed | Eli Lilly | 7 | |
| NCT00482014Carcinoma, Non-Small-Cell Lung · United States, India | 2 | Completed | Eli Lilly | Oct 2011 | 120 |
| NCT00407407Fallopian Tube Neoplasms · United States | 1 | Terminated | Bristol-Myers Squibb | Feb 1, 2008 | 6 |
| NCT00402051Carcinoma, Non-Small-Cell Lung · Germany | 2 | Completed | Eli Lilly | Dec 2008 | 133 |
| NCT00365365Breast Neoplasms · United States | 2 | Completed | Sanofi | Oct 2011 | 214 |
| NCT00356525Lung Neoplasms · United States, Brazil, India | 2 | Terminated | Eli Lilly | Jun 2008 | 41 |
| NCT00350792Carcinoma, Non-Small-Cell Lung · France | 2 | Completed | Eli Lilly | Nov 2008 | 62 |
| NCT00343291Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Eli Lilly | May 2010 | 121 |
| NCT00325234Breast Neoplasms · Germany, Italy, South Africa and more | 2 | Completed | Eli Lilly | Apr 2010 | 135 |
| NCT00303108Breast Neoplasms · United States | 2 | Completed | Sarah Cannon Research Institute | Mar 2010 | 136 |
| NCT00269152Carcinoma, Non-Small-Cell Lung · France, Germany, Spain | 2 | Completed | Eli Lilly | Nov 2007 | 122 |
| NCT00258739Lung Neoplasms · Spain | 2 | Completed | Sanofi | Sep 2007 | 140 |
| NCT00248287Breast Neoplasms · United States | 2 | Active, not recruiting | Sarah Cannon Research Institute | Dec 2025 | 154 |
| NCT00191854Breast Neoplasms · Brazil, China, India and more | 2 | Completed | Eli Lilly | Aug 2008 | 147 |
| NCT00191451Breast Neoplasms · United States | 2 | Completed | Eli Lilly | Oct 2008 | 150 |
How it is read
Names in the registry
- “Carboplatin”, 110 entries
- “carboplatin”, 38 entries
- “Pemetrexed/Carboplatin”, 2 entries
- “CARBOPLATIN”, 2 entries
- “Carboplatin/Paclitaxel”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 72 studies
- Ovarian Neoplasms, 22 studies
- Breast Neoplasms, 17 studies
- Small Cell Lung Carcinoma, 10 studies
- Neoplasms, 8 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.